{"id":"tadalafil-pill","safety":{"commonSideEffects":[{"rate":"15–20%","effect":"Headache"},{"rate":"10–15%","effect":"Dyspepsia"},{"rate":"6–12%","effect":"Back pain"},{"rate":"5–10%","effect":"Myalgia"},{"rate":"3–8%","effect":"Flushing"},{"rate":"3–7%","effect":"Nasal congestion"},{"rate":"1–3%","effect":"Vision abnormalities"}]},"_chembl":{"chemblId":"CHEMBL779","moleculeType":"Small molecule","molecularWeight":"389.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking PD5, tadalafil prevents the breakdown of cyclic GMP, allowing sustained smooth muscle relaxation in penile tissue and increased vasodilation. This mechanism also applies to pulmonary and systemic vasculature, explaining its use in pulmonary hypertension and benign prostatic hyperplasia. The drug's long half-life (17–21 hours) enables once-daily dosing for chronic conditions.","oneSentence":"Tadalafil inhibits phosphodiesterase type 5 (PD5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and improve blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:55.392Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Erectile dysfunction"},{"name":"Pulmonary arterial hypertension"},{"name":"Benign prostatic hyperplasia"},{"name":"Pulmonary hypertension associated with chronic thromboembolic disease"}]},"trialDetails":[{"nctId":"NCT03229889","phase":"PHASE4","title":"Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2017-06-07","conditions":"Nephrolithiasis","enrollment":220},{"nctId":"NCT04684589","phase":"PHASE2","title":"Effect of PDE5 Inhibition on Adipose Metabolism in Humans","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-03-16","conditions":"Obesity","enrollment":89},{"nctId":"NCT05558007","phase":"PHASE2","title":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","status":"RECRUITING","sponsor":"Biozeus Biopharmaceutical S.A.","startDate":"2023-11-22","conditions":"Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer","enrollment":72},{"nctId":"NCT06184334","phase":"NA","title":"Management of OAB in Female Patients .","status":"COMPLETED","sponsor":"Elsayed Abdelhalim Elsayed","startDate":"2022-09-14","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT02819440","phase":"PHASE2","title":"PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-07","conditions":"Healthy, Obese","enrollment":141},{"nctId":"NCT03641846","phase":"NA","title":"Low-intensity Shockwave Therapy (LiST) for the Treatment of Mild and Mild-to-moderate Vasculogenic Erectile Dysfunction","status":"COMPLETED","sponsor":"Institute for the Study of Urological Diseases, Greece","startDate":"2018-08-28","conditions":"Erectile Dysfunction, Low Intensity Shockwave Therapy","enrollment":50},{"nctId":"NCT04946162","phase":"PHASE4","title":"The Use of Tadalafil in Confirmed COVID-19 Pneumonia.","status":"WITHDRAWN","sponsor":"Santa Barbara Cottage Hospital","startDate":"2020-04-20","conditions":"COVID, Sars-CoV2, ARDS, Human","enrollment":""},{"nctId":"NCT04052269","phase":"PHASE3","title":"Phosphodiesterase Inhibitors in Glaucoma Study (PhiGS)","status":"SUSPENDED","sponsor":"Imperial College London","startDate":"2019-06-21","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT00894413","phase":"PHASE2","title":"A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-05-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT01275339","phase":"PHASE4","title":"Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-12","conditions":"Aortic Stenosis, LV Remodeling, Hypertrophy","enrollment":10},{"nctId":"NCT03309592","phase":"PHASE4","title":"Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2017-10-12","conditions":"Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver","enrollment":""},{"nctId":"NCT01272388","phase":"PHASE4","title":"Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-01","conditions":"Aortic Stenosis","enrollment":1},{"nctId":"NCT02999906","phase":"PHASE3","title":"Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-10","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01291069","phase":"PHASE1","title":"Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2011-09","conditions":"Single Ventricle","enrollment":20},{"nctId":"NCT01444651","phase":"PHASE3","title":"A Trial of Tadalafil and Glycemic Traits","status":"COMPLETED","sponsor":"Thomas J. Wang, MD","startDate":"2011-08","conditions":"Cardiovascular Disease, Insulin Resistance, Glucose Intolerance","enrollment":73},{"nctId":"NCT00538564","phase":"PHASE2","title":"Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2006-11","conditions":"Sickle Cell Anemia, Priapism","enrollment":""},{"nctId":"NCT01070511","phase":"PHASE4","title":"Tadalafil in Becker Muscular Dystrophy","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-01","conditions":"Becker Muscular Dystrophy","enrollment":48},{"nctId":"NCT01302444","phase":"PHASE4","title":"Treprostinil Combined With Tadalafil for Pulmonary Hypertension","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2011-03","conditions":"Pulmonary Arterial Hypertension","enrollment":1},{"nctId":"NCT01743911","phase":"NA","title":"Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2010-09","conditions":"Hypertension","enrollment":20},{"nctId":"NCT00707187","phase":"PHASE2","title":"Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction","status":"COMPLETED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2001-07","conditions":"Systemic Sclerosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adcirca"],"phase":"marketed","status":"active","brandName":"Tadalafil Pill","genericName":"Tadalafil Pill","companyName":"Santa Barbara Cottage Hospital","companyId":"santa-barbara-cottage-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tadalafil inhibits phosphodiesterase type 5 (PD5) in the corpus cavernosum, increasing cyclic GMP levels to promote smooth muscle relaxation and improve blood flow. Used for Erectile dysfunction, Pulmonary arterial hypertension, Benign prostatic hyperplasia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}